CollPlant

Products and Technologies for Regenerative and Aesthetic Medicine

Health Tech & Life Sciences
Public on NASDAQ on Dec 2010
Mature Rehovot, Israel Founded 2004
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$93.7M
Last: 2026-06
Stage
Mature
Founded
2004
Headcount
62
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences

About

CollPlant is a regenerative and aesthetic medicine company developing technologies and products for tissue regeneration and organ manufacturing.

Its revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, CollPlant is developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Funding history · 15 rounds · $93.7M total

2026-06
$2.6M
2026-02
$2.0M
2025-05
2021-02
2020-02
2019-09
2017-11
$7.4M
Meitav Dash
2017-09
2013-10
2012-11
2012-02
2008-04
2007-04
2007-02
2006-09
$1.5M

Q&A

What is CollPlant's primary focus?
CollPlant is a regenerative and aesthetic medicine company that develops technologies and products for tissue regeneration and organ manufacturing.
What is CollPlant's core technology?
CollPlant's core technology is a plant-based method for the mass production of recombinant human Type I collagen (rhCollagen), which is identical to human collagen.
When did CollPlant go public on NASDAQ?
CollPlant went public on NASDAQ in December 2010 with a public offering of $5.5 million.
What was a significant funding event for CollPlant in February 2021?
In February 2021, CollPlant raised $35 million in a funding round.
What was the most recent funding round for CollPlant?
CollPlant's most recent funding round occurred in June 2026, raising $2.6 million.
What is the employee count for CollPlant?
CollPlant has 51-200 employees.
What was a key development in CollPlant's dermal filler product in November 2023?
In November 2023, CollPlant Biotechnologies announced that a patent was granted in the U.S. for its photocurable dermal filler.
What was a notable achievement for CollPlant in June 2023?
In June 2023, CollPlant achieved a milestone and was set to receive $10 million from AbbVie in accordance with their regenerative dermal filler product collaboration agreement.
What new product did CollPlant launch in November 2022?
In November 2022, CollPlant expanded its rhCollagen-based Bioink platform with the launch of Collink.3D™ 90.
What collaboration did CollPlant announce in November 2022?
In November 2022, CollPlant, Tel Aviv University, and Sheba Medical Center joined forces to co-develop an rhCollagen-based 3D bioprinted human intestine model for drug discovery and personalized treatment of ulcerative colitis.

Team · 1

Oded Shoseyov
Founder · Founder, Chief Scientist
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenesMachinery & Robotics3D Printing & Additive Manufacturing
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticals
Business model
B2B

Highlights

Verified

Tags

orthopedicsregenerative-medicinebiomaterialstissue-regenerationpharmaceuticalstreatmentsmedical-devicesnanotechnology3d-technologydrug-deliverymedical-productsmedical-technologies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)